华大基因(300676) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 1,430,136,393.71, a decrease of 8.52% compared to CNY 1,563,364,152.52 in the same period last year[3]. - Net profit attributable to shareholders was CNY 330,415,233.13, down 37.06% from CNY 524,980,701.18 year-on-year[3]. - Basic earnings per share decreased to CNY 0.8050, down 37.64% from CNY 1.2909 in the same period last year[3]. - Total operating revenue for the current period is ¥1,430,136,393.71, a decrease of 8.5% from ¥1,563,364,152.52 in the previous period[25]. - Net profit for the current period is ¥331,838,700.63, down 37.5% from ¥532,043,622.65 in the previous period[26]. - Basic earnings per share decreased to ¥0.8050 from ¥1.2909 in the previous period, reflecting a decline of 37.5%[27]. - The total comprehensive income attributable to the parent company was ¥308,265,143.22, down from ¥535,517,006.82 in the previous period[27]. Cash Flow - The net cash flow from operating activities was -CNY 674,271,200.18, a decline of 609.82% compared to CNY 132,257,506.56 in the previous year[3]. - Cash inflow from operating activities totaled ¥1,083,988,174.49, down 38.2% from ¥1,751,454,996.43 in the previous period[28]. - The company reported a total cash outflow from operating activities of 1,758,259,374.67 CNY, compared to 1,619,197,489.87 CNY in the previous year[29]. - The net cash flow from investment activities was 550,766,682.69 CNY, a recovery from -614,055,864.17 CNY in the same quarter last year[29]. - Cash outflow from financing activities was 370,828,437.11 CNY, slightly higher than 350,138,025.17 CNY in the previous year[29]. - The net cash flow from financing activities was -316,716,362.11 CNY, compared to a positive 1,652,959,099.83 CNY in the prior year[29]. - The total cash and cash equivalents at the end of the period were 6,031,841,341.23 CNY, down from 6,608,444,108.16 CNY year-over-year[29]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,425,986,096.83, a decrease of 5.81% from CNY 14,254,029,629.93 at the end of the previous year[3]. - The company's total liabilities decreased to CNY 3.99 billion from CNY 4.81 billion, a reduction of approximately 17.2%[23][24]. - Current liabilities totaled CNY 3.20 billion, down from CNY 3.38 billion, indicating a decrease of about 5.3%[23]. - The company's total equity decreased slightly to CNY 9.43 billion from CNY 9.44 billion, a marginal decline of about 0.1%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,453, with the largest shareholder holding 35.94%[8]. - Shenzhen BGI Technology Co., Ltd. holds 148,773,893 shares, all of which are pledged[12]. - The top ten shareholders include Shenzhen Qianhai BGI Investment Enterprise (Limited Partnership) with 34,470,455 shares (8.33%) and Bank of Communications Co., Ltd. with 10,000,069 shares (2.42%)[10]. - The company has a total of 151,763,693 restricted shares at the end of the reporting period, with 3,525 shares released during the period[12]. - The largest shareholder, Wang Jian, has 1,903,350 shares under lock-up conditions[12]. Investment and Financing Activities - The company issued bonds in 2020 with a total scale of 500 million RMB, with a coupon rate of 3.50%[13]. - The company’s bonds have a credit rating of AAA, and the issuer's credit rating is AA[13]. - The company completed interest payments for bonds "20华大01" and "20华大02" totaling RMB 17.5 million during the reporting period[14]. - The company decided to redeem all bonds at a price of RMB 103.50 per bond, amounting to a total redemption of RMB 500 million[14]. - The company announced a share repurchase plan with a total amount between RMB 130 million and RMB 260 million, with a maximum repurchase price of RMB 130 per share[17]. - The company repurchased 4,000,099 shares, accounting for 0.9664% of the total shares, with a total expenditure of RMB 336.34 million[18]. Research and Development - Research and development expenses increased by 40.99% to CNY 131,377,761.41, reflecting the company's commitment to enhancing R&D investment[6]. - Research and development expenses increased to ¥131,377,761.41, up 41.0% from ¥93,182,661.31 in the previous period[25]. Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[10]. - There are no indications of mergers or acquisitions in the current reporting period[10]. - The company did not undergo an audit for the first quarter report[30].